Previous 10 | Next 10 |
Galmed Pharmaceuticals Ltd. (GLMD) Q2 2019 Earnings Conference Call August 5, 2019 8:30 A.M. ET Company Participants Allen Baharaff - President and Chief Executive Officer Yohai Stenzler - Chief Financial Officer Tali Gorfine - Chief Medical Officer Liat Hayardeny - Chief Scien...
Galmed (NASDAQ: GLMD ): Q2 GAAP EPS of -$0.20 beats by $0.02 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of...
TEL AVIV, Israel , July 29, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalcoh...
Introduction Madrigal Pharmaceuticals ( MDGL ), Galmed Pharmaceuticals ( GLMD ), and Galectin Therapeutics ( GALT ) are small or mid-cap clinical stage biopharmas with a common unifying clinical goal of developing effective therapeutics for NASH disease. Madrigal (Resmetirom), Galmed (Aram...
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai Stenzler - Chief Finan...
Galmed (NASDAQ: GLMD ): Q1 GAAP EPS of -$0.17 beats by $0.04. More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoh...
TEL AVIV, Israel , April 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalco...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...